The Directorate General of Trade Remedies (DGTR) on September 28, 2026, has initiated an anti-dumping investigation on imports of Penicillin-G and its salts originating in or exported from China PR, following an application by Lyfius Pharma Private Limited. The product, used primarily as a key starting material/API for pharmaceutical manufacturing, is classified under tariff heading 2941 10 10. The investigation covers the period April 1, 2025 to March 31, 2026, with the injury period covering 2022-23, 2023-24, 2024-25 and the period of investigation. DGTR has found prima facie evidence of dumping above the de minimis level and material retardation to the establishment of the domestic industry due to the adverse impact of Chinese imports on production, capacity utilisation, prices and financial performance.
Interested parties are required to register on the SETU Portal under Case ID AD/OI/057/2026 and submit their questionnaire responses and other relevant information within 37 days from transmission of the prescribed intimation letters. Comments on the scope of the product under consideration and PCN methodology must be submitted within 15 days, concurrently with the above timeline. Confidential submissions must be accompanied by separate, meaningful non-confidential versions, failing which the submissions may not be considered. DGTR will examine the dumping, injury and causal link and determine whether anti-dumping duty should be recommended; the applicant's request for provisional anti-dumping duty will be considered at the appropriate stage.
[SETU CASE ID - AD/OI/057/2026]
